Andrea Eleazar, MHS

Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.

Phase 3 FLASH2 ends early after interim analysis shows synthetic hypericin photodynamic therapy fails to improve CTCL outcomes, prompting deeper data review and regulator talks.

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.

Real-world data show community oncology care links to longer survival in metastatic breast cancer and NSCLC, beating national benchmarks.

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows rapid deep molecular responses and tolerable safety.

Study finds Gemini and GPT catch oncology chart errors, improving documentation accuracy and patient safety with clinician oversight.

Advanced genomic profiling in community oncology uncovers actionable cancer mutations and trial options—yet insurance denials still block access.

Odronextamab delivers higher responses and longer control in later-line follicular lymphoma versus real-world therapies, new analysis reports.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

Nearly 60% of under-50 cancers are screen-detectable; Ohio State’s BRIDGE program coordinates care, research, and support for younger adults.

Why oncology telehealth stalls: patients cite platform anxiety, few video offers, and in-person trust—pointing to hybrid care.

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.

New data show precision cancer testing still lags for Black, Hispanic, low-income, and Medicare/Medicaid patients, delaying targeted treatment decisions.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

Same-day multidisciplinary clinics could shorten time to treatment, boost guideline adherence, and improve satisfaction in solid tumor care, a review finds.

FDA confirms brexu-cel CAR-T for relapsed mantle cell lymphoma, citing 91% response in BTK-naive patients and updated safety guidance.

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Young US cancer survivors face outsized food, housing and transport insecurity; Medicaid expansion and targeted SDOH screening may improve survivorship.

Second-line axi-cel CAR T boosts quality of life in relapsed large B-cell lymphoma, with early dip then lasting recovery for older patients.

Venetoclax plus ibrutinib shows deep, durable responses in marginal zone lymphoma, with promising 5-year PFS and manageable safety in phase 2 AIM study.

Ten-year trial shows CD22 CAR T drives deep remissions in relapsed pediatric B-ALL, with transplant boosting durability and manageable toxicity.

Post-transplant gilteritinib maintenance may boost survival and reduce relapse in relapsed FLT3-mutated AML, though larger trials are still needed.

Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors.

Phase 1 expansion shows Varseta-M delivers notable response rates and manageable safety in heavily pretreated metastatic colorectal cancer, with FDA registrational planning underway.

FDA signals accelerated path for givastomig in CLDN18.2+ gastric/GEJ cancer, as phase 1b data show strong responses and tolerability.

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Interim phase 1b results show off-the-shelf CD19 CAR T azer-cel drives high response rates in hard-to-treat CLL/SLL and MZL.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.